Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation
This study presents strong evidence confirming the safety and therapeutic potential of Pt@PCN-Cu in PDAC treatment. Importantly, Pt@PCN-Cu not only induces cuproptosis but also significantly enhances antitumor efficacy in combination with αPD-L1 by regulating PD-L1 expression through HK2 modulation. These findings underscore a more effective and innovative approach for treating PDAC.
Authors
- C Ma (ORCID: https://orcid.org/0000-0001-5236-8374)
- Yidan Song
- Yukuan Feng (ORCID: https://orcid.org/0009-0005-6497-0748)
- Xingjiang Li (ORCID: https://orcid.org/0000-0002-5455-8240)
- Weihua Guo (ORCID: https://orcid.org/0000-0002-5839-7114)
- Lantao Liu (ORCID: https://orcid.org/0000-0002-8025-7222)
- Jihui Hao (ORCID: https://orcid.org/0000-0002-1607-1730)
- Pengyu Wang (ORCID: https://orcid.org/0000-0002-6904-5499)
- Jiaqi Li (ORCID: https://orcid.org/0000-0002-8308-9850)
- Yang Yang (ORCID: https://orcid.org/0000-0002-9911-7123)
- Wanying Zhang (ORCID: https://orcid.org/0000-0001-9874-9834)
- Yan Geng
- Shuyue Liu (ORCID: https://orcid.org/0000-0001-9890-8049)
- Jing Hu
- Pei Cao (ORCID: https://orcid.org/0000-0002-4240-5124)
- Shouyi Li
- Fengyi Yin
- Bowen Ding (ORCID: https://orcid.org/0000-0002-8957-3379)
Institutions
- Mudanjiang Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1186/s13046-025-03409-4
- Citations
- 12
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 8.09